button bars forest bayes pooled summary circles
 
DOR

R/R cHL - second line or more (L2) refractory classic Hodgkin lymphoma (R/R cHL) R/R cHL - second line or more (L2)

versus brentuximab vedotin
pembrolizumab alone vs. brentuximab vedotin 1 -

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons